Valuation : Turn Therapeutics Inc.

Market Cap 288M 249M 234M 213M 399M 27.21B 402M 2.77B 1.08B 13.91B 1.08B 1.06B 45.7B P/E 2026 *
-24.2x
P/E 2027 * -24.8x
Enterprise Value 288M 249M 234M 213M 399M 27.21B 402M 2.77B 1.08B 13.91B 1.08B 1.06B 45.7B EV / Sales 2026 *
576x
EV / Sales 2027 * 57.6x
Free-Float
45.25%
Yield 2026 *
-
Yield 2027 * -
1 day-1.53%
1 week+0.42%
Current month+0.73%
1 month+15.67%
3 months+50.62%
6 months+164.21%
Current year+145.43%
1 week 9
Extreme 9
10.28
1 month 8.58
Extreme 8.58
10.95
Current year 3.01
Extreme 3.01
11.69
1 year 2.57
Extreme 2.5701
26.5
3 years 2.57
Extreme 2.5701
26.5
5 years 2.57
Extreme 2.5701
26.5
10 years 2.57
Extreme 2.5701
26.5
Manager TitleAgeSince
Chief Executive Officer 48 06/01/2015
Director of Finance/CFO 31 01/05/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 48 -
Director/Board Member 46 01/10/2018
Director/Board Member 61 01/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
28/05/26 Don

Chief Executive Officer

-1,200,000 4.0285%
02/04/26 Don

Chief Executive Officer

300,000 1.0188%
02/04/26 Don

Director

300,000 1.0188%
Change 5-day change 1-year change 3-year change Capi.($)
-1.53%+0.42% - - 293M
+1.03%-3.11%+39.80%+94.60% 68.21B
+1.62%+0.33%+48.61%+88.33% 64.25B
+4.21%+1.80%-12.85%+459.32% 26.54B
+1.83%-7.77%+3.17%-14.74% 25.61B
+1.30%+0.74%+31.66%-17.99% 19.88B
-0.38%-12.42%+224.86%+373.18% 17.13B
+0.65%-5.28%-1.12%+544.44% 14.93B
+2.88%+4.33%+57.42%+157.39% 14.1B
+1.53%+1.49%+25.41%+195.41% 12.45B
Average +1.31%-2.97%+46.33%+208.88% 26.34B
Weighted average by Cap. +1.60%-2.70%+42.45%+162.51%

Financials

2026 *2027 *
Net sales 500K 431K 406K 370K 692K 47.23M 697K 4.81M 1.87M 24.15M 1.88M 1.84M 79.33M 5M 4.31M 4.06M 3.7M 6.92M 472M 6.97M 48.11M 18.67M 241M 18.78M 18.37M 793M
Net income - -
Net Debt - -
Logo Turn Therapeutics Inc.
Turn Therapeutics Inc. is a pharmaceutical and medical device development company built around a proprietary platform of technology designed to enhance drug performance. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.
Employees
-
Date Price Change Volume
02/09/26 $9.670 -1.53% 106,426
01/09/26 $9.820 +2.29% 43,211
31/08/26 $9.600 -2.44% 31,635
28/08/26 $9.840 -2.67% 62,760
27/08/26 $10.11 +4.98% 47,598
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
9.670USD
Average target price
26.00USD
Spread / Average Target
+168.87%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TTRX Stock